Immunic Inc. Stock
Immunic Inc. Stock
We see a rather positive sentiment for Immunic Inc. with 17 Buy predictions and 1 Sell predictions.
Based on the current price of 0.75 € the target price of 6 € shows a potential of 702.14% for Immunic Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Immunic Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Immunic Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Immunic Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Immunic Inc. | - | - | - | - | - | - | - |
| Ocuphire Pharma Inc. | 9.210% | 2.256% | -22.727% | 165.107% | 61.712% | -25.275% | -27.273% |
| NanoViricides Inc. | 0.000% | 3.759% | 16.949% | -4.167% | 48.387% | 0.730% | -61.667% |
| Actinium Pharmaceuticals Inc. | 2.040% | -7.905% | -14.750% | -47.684% | -39.188% | -88.441% | -87.235% |
Comments
Immunic (IMUX) had its price target lowered by B. Riley Financial, Inc. from $40.00 to $27.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (IMUX) is now covered by Wolfe Research. They set an "outperform" rating on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (IMUX) had its "buy" rating reaffirmed by Roth Mkm.
Show more
Ratings data for IMUX provided by MarketBeat
News
EQS-News: Immunic to Participate in Investor Conferences in July
EQS-News: Immunic to Participate in Investor Conferences in July
EQS-News: Immunic to Participate in Investor, Industry and Scientific Conferences in June
EQS-News: Immunic to Participate in Investor, Industry and Scientific Conferences in June
EQS-News: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
EQS-News: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis